Stay updated with breaking news from Agenus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Continued Strategic Progress in Challenging Markets Webcast Available at 7:01AM BST, 2.01 EDT Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results
Analysts expect Agenus Inc. (NASDAQ:AGEN – Get Rating) to announce sales of $18.70 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Agenus’ earnings, with the lowest sales estimate coming in at $15.00 million and the highest estimate coming in at $21.09 million. Agenus reported sales of $10.73 […]
Genus plc (LON:GNS – Get Rating) has earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that […]
New deal enables Oxford BioTherapeutics (OBT) to evaluate OBT076 with a checkpoint inhibitor (CPI) in both CPI-naïve and resistant patientsOBT076 has previously shown preliminary signs of clinical
Agenus Inc. (NASDAQ:AGEN – Get Rating) – Equities researchers at B. Riley lifted their Q2 2022 EPS estimates for shares of Agenus in a research note issued on Wednesday, May 11th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn ($0.23) per share for the quarter, up from their prior forecast […]